Eli Lilly and Co (NYSE:LLY) has announced the launch of its Humalog Junior KwikPen and also announced the availability of the device via prescription for diabetes treatment in the U.S.
The company was proud to reveal the Humalog Junior KwikPen as the only unique product of its kind in the market. It is a disposable half-unit pen that contains insulin and can be used by type 1 and type 2 diabetes patients to manage the condition. The Humalog Junior KwikPen received approval for the treatment of diabetes from the Food and Drug Administration in June this year. It also received support from the Committee for Medicinal Products for Human Use (CHMP) in September 2017 following a positive opinion from the committee.
“Learning how to inject insulin can be overwhelming, especially for newly diagnosed children and their caregivers. People often feel shock and anxiety, and may struggle with the reality of fitting diabetes into daily life,” stated Sherry Martin, the VP of Global Medical Affairs at Lilly Diabetes.
Martin also added that the company hopes to eliminate some of the worries that diabetes patients usually have when it comes to the injection process. She also added that the Humalog Junior KwikPen is the ideal product for patients who have worries about the injection process because the device is quite easy to use and it is prefilled. It also features half-unit increments for precise dosage.
The new pen is lighter and shorter than other half-unit pens and its disposable nature makes it ideal for most patients. Before its launch, the only way that patients could inject half units of insulin was by using reusable pens. This method is not as straightforward and requires a bit of getting used to since patients have to remove and reload the cartridges.
Lilly hopes that the Humalog Junior KwikPen quickly become an attractive product on the market that will improve the lives of the patients. The firm is also optimistic about the revenue potential that the new product stands to deliver.
Eli Lilly and Co stock closed the latest trading session on Thursday at $87.65, after moving upwards by 0.79%.
